Ocular Therapeutix, Inc. (OCUL) is a publicly traded Healthcare sector company. As of May 21, 2026, OCUL trades at $8.06 with a market cap of $1.83B and a P/E ratio of -5.63. OCUL moved +0.38% today. Year to date, OCUL is -30.48%; over the trailing twelve months it is +5.66%. Its 52-week range spans $5.79 to $16.44. Analyst consensus is strong buy with an average price target of $24.50. Rallies surfaces OCUL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ocular Therapeutix Q1 Loss of $88.6M, AXPAXLI Phase 3 Shows 65.9% Vision Maintenance: Ocular Therapeutix reported a Q1 loss of $88.6M (40¢ per share) on $10.8M revenue, missing estimates of 32¢ and $12.7M. The company holds $666.7M cash runway to 2028 and plans an NDA for AXPAXLI after Phase 3 SOL-1 showed 65.9% vision maintenance at Week 52 versus 44.2% with aflibercept.
| Metric | Value |
|---|---|
| Price | $8.06 |
| Market Cap | $1.83B |
| P/E Ratio | -5.63 |
| EPS | $-1.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.44 |
| 52-Week Low | $5.79 |
| Volume | 9.04K |
| Avg Volume | 0 |
| Revenue (TTM) | $52.04M |
| Net Income | $-290.50M |
| Gross Margin | 87.24% |
9 analysts cover OCUL: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.50.